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Abstract
Background: Extreme obesity affects nearly 8% of Canadians, and is debilitating, costly and ultimately lethal.
Bariatric surgery is currently the most effective treatment available; is associated with reductions in morbidity/
mortality, improvements in quality of life; and appears cost-effective. However, current demand for surgery in
Canada outstrips capacity by at least 1000-fold, causing exponential increases in already protracted, multi-year wait-
times. The objectives and hypotheses of this study were as follows: 1. To serially assess the clinical, economic and
humanistic outcomes in patients wait-listed for bariatric care over a 2-year period. We hypothesize deterioration in
these outcomes over time; 2. To determine the clinical effectiveness and changes in quality of life associated with
modern bariatric procedures compared with medically treated and wait-listed controls over 2 years. We
hypothesize that surgery will markedly reduce weight, decrease the need for unplanned medical care, and increase
quality of life; 3. To conduct a 3-year (1 year retrospective and 2 year prospective) economic assessment of bariatric
surgery compared to medical and wait-listed controls from the societal, public payor, and health-care payor
perspectives. We hypothesize that lower indirect, out of pocket and productivity costs will offset increased direct
health-care costs resulting in lower total costs for bariatric surgery.
Methods/design: Population-based prospective cohort study of 500 consecutive, consenting adults, including 150
surgically treated patients, 200 medically treated patients and 150 wait-listed patients. Subjects will be enrolled
from the Edmonton Weight Wise Regional Obesity Program (Edmonton, Alberta, Canada), with prospective bi-
annual follow-up for 2 years. Mixed methods data collection, linking primary data to provincial administrative
databases will be employed. Major outcomes include generic, obesity-specific and preference-based quality of life
assessment, patient satisfaction, patient utilities, anthropometric indices, cardiovascular risk factors, health care
utilization and direct and indirect costs.
Discussion: The results will identify the spectrum of potential risks associated with protracted wait times for
bariatric care and will quantify the economic, humanistic and clinical impact of surgery from the Canadian
perspective. Such information is urgently needed by health-service providers and policy makers to better allocate
use of finite resources. Furthermore, our findings should be widely-applicable to other publically-funded
jurisdictions providing similar care to the extremely obese.
Trial Registration: Clinicaltrials.gov NCT00850356
* Correspondence: rpadwal@ualberta.ca
1Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Full list of author information is available at the end of the article
Padwal et al. BMC Health Services Research 2010, 10:284
http://www.biomedcentral.com/1472-6963/10/284
© 2010 Padwal et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Obesity currently affects 24% of Canadians [1] and is a
chronic medical condition that leads to substantial mor-
bidity,[2] premature mortality,[3] impaired quality of life
(QOL),[4] and increased health care costs [5]. Obesity is
most commonly defined according to body mass index
(BMI), with BMI levels of 30-34.9, 35-39.9 and over 40
kg/m
2 corresponding to Class I, II and III obesity,
respectively. Extreme obesity, defined herein as patients
with moderate or severe obesity, is the fastest growing
obesity subgroup affecting nearly 8% of Canadians [6].
Extreme obesity has increased in prevalence in Canada
by 400% in two decades;[5] increases the risk of type 2
diabetes by up to 18-fold compared to normal-weight
individuals;[2] shortens life expectancy by 8-13 years;[7]
increases work-absenteeism;[8] and dramatically reduces
QOL,[4] productivity,[9] and employability [10]. Health
care expenditures in the 3% of the employed US popula-
tion that are severely obese account for 21% of all health
care costs associated with obesity [11].
Bariatric Surgery for Extreme Obesity
Lifestyle modification (diet, exercise ± behavioural ther-
apy) and pharmacotherapy for obesity each reduce
weight by approximately 3-5% but are limited by poor
long-term effectiveness and sub-optimal adherence
[12,13]. In comparison, bariatric surgery leads to sub-
stantial weight reduction and has emerged an effective
means to reduce weight and improve comorbidity in
patients with extreme obesity [14]. Surgery is currently
indicated in medically refractory patients with BMI
levels of ≥ 40 kg/m
2 or BMI levels of ≥ 35 kg/m
2 with a
major obesity-related comorbidity (e.g., hypertension,
diabetes, sleep apnea) [14].
Bariatric procedures either involve stomach restriction
alone or combined restriction plus intestinal diversion.
The types of procedures performed have evolved over
the past several decades and certain procedures, such as
banded gastroplasty, have been abandoned due to poor
long-term weight loss results. In Canada and globally,
the most common operations performed are adjustable
gastric banding (42%), Roux-en-y gastric bypass (40%)
and sleeve gastrectomy (5%). Ninety percent of bariatric
procedures are performed via laparoscopic (minimally
invasive) techniques [15]. In gastric banding, the proxi-
mal stomach is encircled with an adjustable band that is
progressively inflated to create a small, restrictive gastric
pouch which reduces meal portions. In the roux-en-y
gastric bypass, a highly restrictive gastric pouch is cre-
ated and coupled with diversion of the upper small
intestine. The sleeve gastrectomy procedure is per-
formed by fashioning the stomach into an elongated
tube and resecting the majority of the greater curve of
the stomach.
Outcomes Associated with Bariatric Surgery
Although no large scale, contemporary randomized con-
trolled trials (RCTs) have examined the impact of sur-
gery on cardiovascular morbidity or overall mortality,
compelling data are available from high quality observa-
tional studies such as the Swedish Obesity Study (SOS),
a matched cohort study of 2010 surgical and 2037 con-
trols [16,17]. Compared to the poor long-term results of
non-surgical therapy, surgery is the only therapy asso-
ciated with substantial improvements in weight (aver-
aging 33% after 2-3 years[18] and 16% after 10 years
[16]); 15-year mortality rates (5.0% versus 6.3% in well-
matched controls; HR 0.71; 95% CI 0.54 to 0.92);[19]
11-year incidence rates of first time cancers (HR 0.67;
95% CI 0.53-0.85);[17] and 7-year mortality rates from
coronary artery disease (HR 0.41; 95% CI 0.21-0.78) and
cancer (HR 0.40; 95% CI 25-0.65) [20]. In terms of other
medical comorbidity, surgery increased remission rates
for type 2 diabetes (73% versus 13%; p < 0.001; OR 5.5;
95% CI 2.2-14) in a 60-patient RCT;[21] and meta-
analyses of primarily observational data has demon-
strated that surgery is associated with resolution or
improvement of type 2 diabetes, hypertension, dyslipide-
mia and sleep apnea in 70-86% of cases [18]. Additional
studies demonstrate that surgery significantly (p < 0.05)
improves psychosocial functioning,[22] quality of life,
[23] and physical function [24].
In terms of Canadian data, a retrospective analysis of
1 0 3 5b a r i a t r i cs u r g e r yp a t i e n t sf r o mas i n g l ep r a c t i c ei n
Quebec reported 5-year excess weight losses of 61-75%
following gastric bypass and banding [25]. In an earlier
study, patients from this bariatric program (n = 1035)
were also retrospectively compared with 5746 age and
sex-matched controls identified using administrative
data claims in Quebec (clinical variables such as height
and weight were not available for controls) [26]. Mortal-
ity rates over 5 years were markedly lower in the baria-
tric surgery cohort compared to controls (0.68% versus
6.17%; RR 0.11, 95% CI 0.04-0.27) although the design
o ft h i ss t u d yc a n n o tr u l eo u tt h ev e r yr e a ll i k e l i h o o d
that surgical selection bias (i.e., healthier and higher
socioeconomic status patients with lower likelihood of
surgical complications more likely to receive surgery)
explains some if not most of these findings.
Risks of Surgery
The complications of surgery can be divided into peri-
operative and long-term complications. The totality of
data suggests that the benefits of surgery far outweigh
these risks [18,27]. Perioperative death rates are 0.1-
0.5% and immediate postoperative complications (e.g.,
clots, cardiorespiratory events and wound infections)
occur in 10% of individuals. Diversionary procedures
increase the long-term risk of nutrient deficiency (up to
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Page 2 of 1150% of patients) while gastric bands can slip (6% of
patients) or erode (10%) necessitating re-operation [27].
Some long-term consequences of surgery such as micro-
nutrient deficiencies (e.g., vitamin D deficiency and
metabolic bone disease) are incompletely understood
and require further study.
Economic Evaluations of Bariatric Surgery
From the payor perspective and relative to the com-
monly cited thresholds of acceptability,[28,29] the long-
term (20 years to lifetime) cost-effectiveness of surgery
compared with non-surgical management appears
attractive. Incremental cost-effectiveness ratios (ICERs)
range from $5000 to $35 000 per quality-adjusted-life-
year (QALY) [30]. The cost-effectiveness of surgery in
patients with type 2 diabetes appears dominant (pro-
vides net health benefits and cost savings) compared to
non-surgical interventions[ 3 1 , 3 2 ] .Ar e c e n tC a n a d i a n
economic evaluation performed by our group from the
health care payor’s perspective estimated that surgery is
associated with ICERs of $8000-10 000/QALY over a
lifetime horizon in Canada, with more favourable ICERs
in subjects with greater obesity related comorbidity [30].
The only other additional published economic data from
the Canadian perspective have been reported from a ret-
rospective cohort study from Quebec. Surgery reduced
health care utilization for a variety of disorders and was
cost saving after 3.5 years compared to matched con-
trols identified through administrative data claims [33].
However, there are limitations to the above studies.
Economic studies based solely upon administrative data
inputs do not include home and workforce productivity
and patient borne costs. Furthermore, cost effectiveness
analyses from the payor perspective do not examine
such costs. Therefore, these additional data elements
would provide a much more accurate picture of overall
costs and benefits from a societal perspective.
Demand, Access and Wait Times For Bariatric Surgery
Demand for bariatric surgery has increased at an expo-
nential rate. The number of procedures performed glob-
ally has increased from 5000 in 1987-9 to 350 000 (63%
in US/Canada) in 2009 [15,34]. In Canada, the annual
number of procedures performed in public health care
facilities in the past decade has increased nearly 19-fold
to ~1500 procedures per year [35,36].
D e s p i t et h i sd r a m a t i cr i s ei nu p t a k e ,t h en u m b e ro f
individuals potentially eligible for surgery greatly exceeds
current surgical capacity. Given that the number of
Canadians potentially eligible for surgery is 5.8% or 1.5
million (assuming a 2009 adult population of nearly 26
million),[37] and that about 1500 procedures are per-
formed annually in Canada,[36] only 0.1% of potentially
eligible patients are accessing surgery in this country.
Therefore, actual demand may be orders of magnitude
greater than current provision of surgery [38].
In Canada and elsewhere, surgery is available in both
publicly and privately funded programs. Private surgery
costs approximately $17 000 in Canada and is unafford-
able to many [39]. However, wait times for publicly
funded bariatric procedures in this country average
5 years,[40] and are similarly protracted in other public
health care systems [41]. This clearly indicates a sub-
stantial demand-supply gap. A 2005 Ontario Ministry of
Health report estimated demand at 3500 surgeries per
year in that province, a 7-fold higher number than the
500 surgeries currently performed annually [42]. This
necessitated outsourcing of procedures to the US at
substantial cost;[42] and resulting in petitions from
advocacy groups demanding improved access [43]. In
2009, Ontario announced $75 million funding to
increase procedure numbers from 244/year to nearly
1500/year [38].
Knowledge Gaps
In summary, the prevalence of extreme obesity has
increased dramatically and bariatric surgery is the most
effective treatment available. However, access to baria-
tric care in Canada is severely limited and wait times
are lengthy. The ramifications of protracted wait times
on health and health care costs have not previously
been examined. In addition, data assessing the clinical
and cost effectiveness of surgery in Canada are limited
and further study is needed. Specifically, a comprehen-
sive, population-based prospective assessment of the
economic consequences from a health care payor, public
payor (health care + other benefits such as unemploy-
ment insurance and other transfer payments), and socie-
tal (public payor, out-of-pocket costs, home and work
productivity costs) perspective has not been performed
to our knowledge in Canada or elsewhere.
Lastly, much of the prospective data evaluating baria-
tric procedures comes from the SOS study. However,
vertical banded gastroplasty, which is now outdated,
comprised nearly 70% of the procedures performed in
SOS. More recent studies have evaluated gastric banding
and gastric bypass and have reported similar results to
SOS in terms of weight reduction and improvement in
obesity-related comorbidities [44,45]. However, no prior
studies comparing sleeve gastrectomy to medical man-
agement and APPLES results will help address this
knowledge gap.
Objectives and Hypotheses
The APPLES study is a population-based, prospective
controlled study enrolling at minimum of 500 patients
and designed to assess the impact of extended wait-
times for bariatric care and examine the clinical and
Padwal et al. BMC Health Services Research 2010, 10:284
http://www.biomedcentral.com/1472-6963/10/284
Page 3 of 11cost-effectiveness of bariatric treatment in the Canadian
context.
The three major objectives of APPLES are:
1. To assess the impact of extended wait times for
bariatric care by examining the two-year change in clini-
cal, economic and humanistic outcomes in wait-listed
patients. We hypothesize that patients will report pro-
gressive deterioration in these outcomes over time.
2. To determine the clinical effectiveness and changes
in health-related quality of life associated with modern
bariatric procedures and compare these outcomes to
medically treated controls and untreated wait-listed con-
trols. We hypothesize that surgery will markedly reduce
body weight, decrease the need for unplanned medical
care, and increase quality of life compared to controls.
3. To compare the costs associated with bariatric sur-
gery to costs associated with medical and wait-listed
controls over three years, from societal, public payor,
and health care payor perspectives. We hypothesize that
lower indirect, out of pocket and productivity costs will
offset increased direct health-care costs resulting in
lower total costs for bariatric surgery.
Methods/design
Overall Study Design
In this prospective cohort study, consecutive and con-
senting patients enrolled in the Weight Wise Regional
Obesity Program and without a contraindication to sur-
gery will be enrolled. The minimum enrolment sample
size will include 150 surgical patients, 200 patients
receiving intensive medical therapy and 150 patients
wait-listed to enter the clinic (Figure 1). The number of
patients enrolled in the medical arm is larger because
we anticipate an increased rate of censoring in this
study arm, as some of these patients will ultimately
undergo bariatric surgery within the two-year follow-up
period.
Study Setting and Subject Recruitment
The Edmonton Weight Wise program is a comprehen-
sive initiative established in 2005 designed to deliver
integrated, patient-focused, evidence-based care to the
Edmonton Zone of Alberta Health Services (AHS). This
region is one of the largest integrated health delivery
systems in Canada and includes a catchment population
of approximately 1 million residents within greater
Edmonton and an additional 600 000 residents in sur-
rounding regions cared for by more than 1000 physi-
cians, with an annual healthcare budget of almost two
billion dollars [46].
Weight Wise includes a central, region-wide single-
point-of-access referral system; community education
and weight management sessions; and adult and pediatric
bariatric specialty clinics. Adult specialty services are
offered to patients with BMI levels of ≥ 35 kg/m
2 referred
from a medical practitioner. By extrapolating from con-
temporary Canadian obesity surveillance data (i.e. ~8% of
Canadians are moderately [BMI 35.0-39.9 kg/m
2]o r
severely [> 40 kg/m
2] obese), we estimate that over 125
000 adult patients within our region’s catchment area has
aB M I≥ 35 kg/m
2 [6]. Community-dwelling patients
referred for evaluation in the adult clinic are wait-listed
at the time of referral (Figure 2). Currently, over 2000
adult patients are wait-listed for entry into the specialty
clinic and their average wait may be up to several years
in duration. Wait-listed patients are expected to attend
community-based group education sessions prior to
clinic entry. Otherwise, they receive no specific
intervention.
Eligibility For Surgery
Within the adult specialty clinic, patients receive
approximately 24-36 weeks of intensive lifestyle counsel-
ling (diet, exercise, behavioural modification), delivered
by a multidisciplinary staff (internists, dieticians, nurses,
physiotherapists, and psychologists) according to current
recommendations [14]. Patients are seen approximately
every 4-8 weeks. Patients interested in bariatric surgery
are also evaluated for this procedure by the same multi-
disciplinary staff. Patients deemed to be appropriate can-
didates are subsequently evaluated by a bariatric
surgeon. Patients with BMI levels ≥ 35-39.9 kg/m
2 and a
major medical comorbidity (e.g., hypertension, type 2
diabetes, sleep apnea) or BMI levels ≥ 40 kg/m
2 are con-
sidered potential candidates for surgery. Absolute con-
traindications to surgery include pregnancy,
uncontrolled psychiatric disease, active substance abuse
or smoking (patients are required to quit prior to sur-
gery), an active eating disorder (anorexia or bulimia),
and high-risk for surgery medical status (e.g. severe cor-
onary artery disease). Because of limited data document-
ing the benefits of surgery in patients younger than 18
years of age and evidence for possible harm in patients
over 60,[47] procedures are not performed in these age
groups. In order to access surgery, patients are also
required to demonstrate commitment to attend sched-
uled appointments and adhere to lifestyle modification
and behavioural therapy.
Inclusion Criteria
1. Male or female patients in the Weight Wise
Regional Obesity Program
2. 18-60 years old
3. BMI levels ≥ 35 kg/m
2 and a major medical
comorbidity or BMI levels ≥ 40 kg/m
2
4. Able to provide informed consent
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1. Pregnant or nursing
2. Currently participating in an obesity-related clini-
cal trial or in whom protein-sparing low calorie diet
is planned.
3. Contraindication to bariatric surgery and/or
weight loss
4. Unable or unwilling to complete questionnaires or
expected to experience difficulty with attendance of
visits or completion of study data
5. Any other medical, social or geographic condition
which, in the opinion of the investigators, would not
allow safe completion of the study protocol
Surgical Procedures Performed
Roux-en-Y gastric bypass, gastric banding and sleeve
gastrectomy are all performed. Surgical techniques have
been previously detailed [30,48,49]. Gastric banding is
performed using the Swedish Adjustable Gastric Band
Figure 1 APPLES Study Design.
Figure 2 Structure of the Adult Component of Weight Wise.
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Page 5 of 11(SAGB) Realize I/II(tm) (Johnson & Johnson/Ethicon
Endosurgery, Cincinnati, Ohio) and sleeve gastrectomies
are created over a 50 Fr bougie using staple line reinfor-
cement throughout. Initially, gastric bypass was per-
formed by hand sewing the gastrojejunostomy over a 34
Fr orogastric tube and positioning of the roux limb was
retrocolic. Over the past two years, the technique has
been modified and a 21 or 25 mm circular stapler is
now used for the gastrojejunostomy pouch, with anteco-
lic positioning of the roux limb. The roux limb is ~100
cm in length. The entero-enterostomy is created using
varying techniques, including a combination of linear
staplers and sutured closure.
Follow-up
Follow-up visits will be scheduled every 6 months for
two years and will be performed in-person or by tele-
phone if necessary. The final two year follow-up visit
will be performed in-person.
Data Collection and Outcome Measures (Additional File 1
and Table 1)
After informed consent is obtained, baseline data collec-
tion for consenting patients will include the following:
age, sex, race, marital status, employment status, house-
hold income quintile (≤ 20 K, 20-40 K, 40-60 K, 60-80
K, ≥80 K), general medical history and obesity-related
comorbidities, smoking status (current, past, never),
detailed current and past medications, weight, BMI,
waist circumference, blood pressure, fasting lipids, fast-
ing glucose, HbA1c, and liver enzymes.
Body weight will be measured using a validated, cali-
brated scale to the nearest 0.1 kilogram after the patient
has emptied his/her bladder. Subjects will wear light
indoor clothing with empty pockets and no shoes.
Height will be measured using a wall-mounted stadio-
metre. A single reading taken using an automated blood
pressure monitor and using an appropriately sized blood
pressure cuff will be recorded with the subject seated in
a chair and after five minutes of rest.
Repeat assessment of blood pressure, body weight, and
cardiovascular risk factors (cholesterol profile, glycemic
parameters) will be performed at 2 years.
Additional outcomes to be collected every 6 months
will include:
1. Household income and employment status
2. Quality of life and utility measurement:H e a l t h
related quality of life will be measured using validated,
widely-used instruments. Generic and preference-based
quality of life will be assessed using the Short Form-12
(SF-12[50]) and the EuroQol-5D (EQ-5D[51]) respec-
tively. Obesity-specific quality of life will be assessed
using the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite) [52].
3. Patient satisfaction: Satisfaction with medical care
will be assessed using two questions, which will be rated
on a 5-point Likert Scale:
a. The medical care I have been receiving is just
about perfect
b. I am dissatisfied with some things about the med-
ical care I received.
4. Impact of Extended Wait Times: The Waiting List
Impact Questionnaire (WLIQ),[53] is a previously vali-
dated 47-item list of open-ended patient statements
designed to assess the impact of extended wait-times in
Canada for coronary bypass surgery and will be adminis-
tered to wait-listed patients. This instrument has been
modified for use in a bariatric population and items
deemed not relevant to the bariatric setting were elimi-
nated, resulting in a 40-item questionnaire. The instru-
ment assesses general quality of life on a scale of 0-100
and also examines specific domains (physical stress, social
support, frustration, employment status), which are serially
evaluated by patients on a 5-point Likert scale. The degree
of interest in bariatric surgery is specifically assessed.
5. Edmonton Obesity Staging Score (EOSS):[54]
EOSS is a recently proposed, preliminary staging system
for obesity which is based upon the presence or absence
of obesity-related comorbities. EOSS will be evaluated as
a triage and prognostic tool within the APPLES cohort.
6. Economic Data (Table 1): Economic data will be
collected for the year prior to enrolment and in the two
years following enrolment. Two major data sources will
be used to collect economic data.
a. Administrative Data:L i n k a g et oA H Sa n d
Alberta Health and Wellness (AHW) administrative
data sources will be performed according to pre-
viously described methods [55,56]. Because all per-
manent residents of Alberta are eligible for
i n s u r a n c eb yA H Wa n do v e r9 9 . 9 %p a r t i c i p a t ei n
this coverage, these administrative data will compre-
hensively capture patient-specific health care
resource utilization. Data elements include vital sta-
tistics (mortality) and the following health care
resources and costs: inpatient and outpatient
encounters, physician billings, medical procedures,
and emergency room visits (Table 1).
b. Patient-Reported: Second, in order to comprehen-
sively capture all economic consequences and enable a
societal perspective, each patient enrolled in the study
will provide additional information retrospectively for
the year prior to enrolment and prospectively for two
years after enrolment on a bi-annual basis. Resource
use will be identified through investigator and clinical
experience as well as examination of comprehensive
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There is no previously validated data collection instru-
ment to measure these costs in obesity; thus, we have
developed a comprehensive instrument using com-
monly used techniques [58,59]. Societal costs include
costs of weight loss interventions (meal replacement,
weight loss programs, alternative therapy, medica-
tions), mobility and medical costs (mobility aids, home
modifications, rehabilitation, home care, housekeep-
ing), workforce productivity (employment, absentee-
ism), home productivity (domestic chores, leisure
activity, use of paid or unpaid caregivers) and transfer
payments (unemployment insurance), and will be
valued in accordance with Canadian guidelines [60].
Statistical Analysis and Sample Size Considerations
Clinical, Humanistic and Economic Outcomes in Wait-listed
Patients
This analysis specifically focuses on the wait-listed group
and will examine two-year change scores in each relevant
outcome using the appropriate statistical methodology.
Analyses will be conducted in all wait-listed patients as
well as those indicating a specific interest in surgery.
Examples of clinical outcomes include anthropometric
indices, blood pressure, lipid profile, glycemic control,
diabetes prevalence. Examples of humanistic outcomes
include QOL and patient satisfaction. Economic out-
comes include total and categorical costs. For example,
two-year change scores will be analysed for QOL
domains (e.g. SF-12, IWQoL-Lite) using appropriately
calibrated and constructed linear regression models and/
or analysis of variance. Because these are self-reported
data collected on a semi-annual basis, we will use a “last-
value carried forward” approach to handle missing data
as our primary analytic strategy.
Sample Size Considerations T h es a m p l es i z eo f1 5 0
subjects provides ample power to detect 2-year change
scores and explore potential independent correlates of
change. For example, for a 2-year change in SF-12
domains such as physical function, with baseline score
of 31.6, SD 9,[61] a clinically important change in QOL
Table 1 Cost categories and details of source data for quantification and valuation of relevant costs
Cost Category
1 Source Details Units of Resources Time Frame
1. Inpatient encounters Administrative data # of hospitalizations
length-of-stay
Provided by fiscal year
Referenced to time zero
2. Outpatient encounters Administrative data # encounters
# procedures
Provided by fiscal year
Referenced to time zero
3. Physician Fees Administrative data # encounters
Provider specialty
Service provided
Provided by fiscal year
Referenced to time zero
4. Medications Patient interview Name
Dosage, frequency & duration
Bi-annual
5. Weight Wise Clinic Visits Administrative data
and chart review
Personnel (nurses, dieticians, support staff) salaries
Administrative and capital costs
Supplies & equipment
Provided by fiscal year
Referenced to time zero
6. Home Care & Long Term Care Patient interview Personnel (nurse, OT, PT, RT) salaries
Disability aids (walker, bars, rails, etc.)
Administrative and capital costs
Bi-annual
7. Transfer Payments Patient interview Unemployment insurance
Disability benefits
Assured Income for the Severely Handicapped (AISH)
Bi-annual
8. Employment status,
absenteeism
Patient interview Employment status in past year (# hours/week, #
weeks)
Absenteeism in past year (# days)
Annual income (by quintile)
Bi-annual
9. Weight Loss Interventions Patient interview Weight loss program, meal replacements, physical
trainer, exercise programs, alternative therapies,
nutritional counselling, commercial program
Bi-annual
10. Mobility and Medical Patient interview Mobility aids, home modification/renovations,
rehabilitation,
paid personal assistance (household activities and
home productivity, driving)
Bi-annual
11. Personal/Household
Productivity
Patient interview as
part of quality of life
surveys
Capacity to perform household/domestic activities,
personal care, and participate in leisure activities
(Scalar)
Paid/unpaid caregivers
Bi-annual
AHCIP = Alberta Health Care Insurance Plan. MACAR = Morbidity and Ambulatory Care Abstracting Record. DAD = Discharge Abstract Database. LOS = Length of
stay. CIHI = Canadian Institute for Health Information. OT = occupational therapy. PT = physiotherapy. RT = respiratory therapy. SW = social worker.
1Health Care Payor perspective includes cost categories 1-6; Public Payor perspective includes cost categories 1-7 and Societal Payor perspective includes all costs.
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30% attrition rate, 48 patients would be required. Simi-
larly, to detect a 2-year change in IWQoL-Lite, with a
baseline score of 28.7, SD 18.7,[61] a clinically important
change in QOL of 10 points,[62] two-sided alpha = 0.05,
beta = 0.90, and a 30% attrition rate, 51 patients would
be required.
Comparing Clinical and Humanistic Outcomes in Patients
Treated with Surgery to Medically Treated and Wait-listed
Patients
Outcomes are similar to those listed above. Two-year
mean changes in continuous variables will be compared
between the surgical arm and medical or wait-listed
controls using unpaired t-tests for continuous outcomes
and chi-squared tests for dichotomous ones. Multivari-
able predictors of the 2-year change in a given outcome
will be identified using appropriately constructed and
calibrated covariate-adjusted linear regression models
for continuous outcomes or logistic regression models
for dichotomous ones. Patients who cross over to
another study arm (e.g., medically treated patients who
undergo surgery) will be censored at the point of cross
over and a last-observation-carried-forward approach to
missing data will be used for the primary analysis.
Sample Size Considerations As an example, we calcu-
lated the sample size required to examine changes in
body weight. Conservatively assuming a 2-year weight
loss of 33% for surgical patients with a standard devia-
tion of 17%,[18,27] a 25% 2-year difference in weight
between surgical patients and intensively treated medical
controls (an extremely conservative estimate, as this dif-
ference is generally several orders of magnitude),[18,27]
a 2-sided a = 0.05, b = 0.9, and 30% attrition rate, we
would require 13 patients.
Comparisons of Costs Over Three Years Between the
Surgical Arm, Medically Treated Controls and Wait-listed
Controls
First, descriptive statistics will be used to assess cumula-
tive and incremental costs (by perspective and cost cate-
gory) in each year using the arithmetic mean and 95%
confidence interval for normally distributed variables
and median with interquartile ranges for skewed vari-
ables. Within and between-group comparisons will be
performed. Distributions of cost are often skewed
and will be normalized, if necessary, by using log-
transformations. Unadjusted analyses of costs will be
performed using ANOVA; if cost cannot be normalized
then nonparametric (e.g., Kruskal-Wallis) tests will be
used. If log-transformation of costs is necessary, Duan’s
smearing estimator will be used to calculate appropriate
error estimates after the data are re-transformed from
the logarithmic scale [63].
Second, covariate controlled sequential multiple linear
regression models will be constructed to determine the
independent association of surgery (versus medical or
wait-list controls) on each incremental cost outcome.
Cumulative costs over time will be calculated using
standardized methods,[64,65]and costs for average
hypothetical patients will be calculated using the least
squares means method, and adjusted for significant pre-
dictor variables for costs for medical and wait-listed
controls.
Third, the net economic impact of increasing bariatric
surgery rates from a societal, public payor, and health
care payor perspective will be assessed using a mathe-
matical model developed by our team. The costs deter-
mined above will be input, and the net economic impact
of increasing rates of bariatric surgery from current
rates (0.1% of eligible patients) to 0.5% (estimated cur-
rent rates in US), 5% and 10% of all eligible patients will
be calculated.
Sample Size Considerations Using previous estimates,
[66] we have adequate power to detect a difference of
20% or greater in costs between the surgical groups and
the medical controls or the wait list controls, assuming
an average 2-year total incremental cost of $12 183 in
surgical patients, a standard deviation of $6000, two
sided alpha = 0.05, and beta = 0.90.
Extended Follow-up
Using anonymised and de-identified study identification
numbers, we will link our study sample with provincial
administrative databases so as to facilitate extended fol-
low-up of health care utilization, clinical events, and
costs. We have undertaken several previous studies link-
ing clinical registry and cohort data with these high
quality databases, and have previously reported greater
than 96% linkage success with follow-up extending 5
years and beyond [55,67].
Ethics Approval
APPLES has been approved by the Health Research
Ethics Board of the University of Alberta.
Discussion
In summary, APPLES is a prospective observational
study that aims to address current knowledge gaps by
examining the impact of wait times for bariatric care in
a surgery eligible population and by generating prospec-
tive, population-based Canadian bariatric clinical, eco-
nomic and humanistic outcome data. Protracted, multi-
year wait times are a major concern within Canada’s
publicly funded health care system [40]. Therefore,
APPLES will help clinicians and decision makers deter-
mine whether or not current wait times are contributing
to a deterioration in health outcomes and/or increases
in costs. If such findings are demonstrated, further ana-
lyses may help to identify predictors of worsening
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Page 8 of 11outcomes and this may potentially inform how best to
triage patients and optimally allocate scarce bariatric
surgery resources. The paucity of data on appropriate
triage of patients for surgery has been identified as a
major gap in current knowledge and is suggested as a
priority for future studies [68].
An additional advantage of the APPLES study design
is that, because subjects are enrolled from a regional
program, the study will examine outcomes and costs on
a population-wide basis rather than from a more
selected source such as a single clinic or group of
clinics. Thus, we feel that the results should both
inform health care delivery in the Canadian context as
well as be generalizable to other single-payor systems
with universal health care coverage. Notably, lengthy
wait times for surgery are not isolated to Canada and
are present in publicly funded health care systems
across the world [41].
APPLES will also provide a comprehensive assessment
of the costs related to bariatric care and will examine
contemporary procedures, including sleeve gastrectomy.
Data will be collected from both administrative and
patient sources within a health care delivery model that
includes universal access and comprehensive capture of
hospital and outpatient encounters. These high quality
costing data will include an assessment of costs com-
monly viewed as ‘indirect’ in nature. Although the time
frame for data collection is limited to 2 years, these data
will also be useful to inform economic models and will
thus enable assessment of cost-effectiveness over a
longer time frame. This will be particularly useful in
more accurately assessing the overall cost-effectiveness
of bariatric surgery in Canada. For example, a finding of
unequivocal cost savings or neutrality from a public
payor perspective would indicate that bariatric surgery is
“dominant” (cost saving with health benefits) over medi-
cal management, and expansion should be a priority.
As of May 2010, 95% of baseline enrolment within
APPLES has been completed. Recruitment of all 500
patients is expected by June 2010, with two-year follow-
up extending to June 2012. Final results for the APPLES
analysis are anticipated by late 2012 or early 2013.
Additional material
Additional file 1: APPLES Case Report Forms. baseline and follow-up
data collection forms for the APPLES study
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